Comparing 1 hypotheses side-by-side
|
NA - Mechanistic hypothesis · neurodegeneration · -
Composite
0.586
Price
$0.51
Evidence For
0
Evidence Against
0
Donanemab-mediated amyloid plaque clearance reduces microglial activation and neuronal injury, attenuating trans-synaptic tau propagation. With reduced neuronal damage, p-tau217 release declines. This mechanistic pathway is biologically plausible but the causal chain (amyloid clearance → reduced neuronal injury → decreased p-tau217) remains unproven. Correlation of temporal sequence does not equal mechanistic causation.
Radar Chart — 10 Dimensions
Score Breakdown
| Dimension | CSF p-tau217 Normalization Ref |
|---|
| Mechanistic | 0.680 |
| Evidence | 0.550 |
| Novelty | 0.600 |
| Feasibility | 0.620 |
| Impact | 0.720 |
| Druggability | 0.250 |
| Safety | 0.650 |
| Competition | 0.700 |
| Data | 0.700 |
| Reproducible | 0.550 |
| KG Connect | 0.500 |
Evidence
CSF p-tau217 Normalization Reflects Amyloid-Driven Tau Patho
No evidence citations yet
Price History Overlay